LONGEVITY with Nathalie Niddam cover image

Episode #129: Weight Loss Results with New GLP-1 Agonist, Mounjaro & Ozempic Comparison

LONGEVITY with Nathalie Niddam

00:00

Ozempic

Mungero is a dual incretin that has activity at GIP receptors and GLP1 receptors. It's got about 51% potency at the GLP1 receptor, which is why even though it results in the same kind of downstream signaling as ozempic, it's not as potent. Anything that reduces blood glucose, anything that reduces area under the curve insulin, right? So from a very fundamental perspective, it's got a huge impact on the basic pathways to aging and so forth. Yeah. If you can live life at a 500 or 600 calorie deficit, if that's that 25% threshold, it gets you your longevity benefit and you don't have to try.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app